Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Crinone Versus Combination Medication (ACCESS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Participants are eligible to be included in the study only if all the following criteria apply:~* Participants who will receive artificial frozen-thawed embryo transfer (FET) cycle study interventions~* Participants who have no more than two Day 5 embryos are planned to be transferred (follow the clinical practice of the study site)~* Participants have received estradiol valerate for no more than 20 days~* Participants have a transitional-endometrium of greater than or equal to 8 millimeter~* Participants have normal uterine cavity~* Participants can give signed informed consent~* Participants are willing to follow the study protocol and able to complete the study~Exclusion Criteria:~* Participants are willing to follow the study protocol and able to complete the study~* Participants with greater than or equal to three previously failed cycles of ET~* Participants with diseases that cannot tolerate pregnancy~* Hydrosalpinx~* Severe endometriosis (Endometriosis American Society for Reproductive Medicine (ASRM) criteria from 1996)~* Known hypersensitivity to progesterone, the excipients of Crinone and Duphaston Vaginal bleeding of unknown origin~* History of recurrent miscarriages~* Vaginitis~* Thromboembolic diseases (thrombophlebitis, thromboembolic disorder, or cerebral apoplexy) or participants with a history of these conditions~* Known or suspected progestogen-dependent neoplasm~* Participation in another clinical trial within the past 30 days~* Contraindications of both Crinone and Duphaston

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 38 Years
- Healthy Volunteers: f

Study Arms:
- Crinone (Type: EXPERIMENTAL): Participants received Crinone 8% (90 milligrams \[mg\] an intravaginal progesterone gel contained in a single use, one piece applicator) once daily in morning from the day of endometrial transformation (Day -5) until ongoing pregnancy was confirmed up to Day 63.
- Crinone plus Duphaston (Type: EXPERIMENTAL): Participants received Crinone 8% (90 mg an intravaginal progesterone gel contained in a single use, one piece applicator) once daily in morning followed by 10 mg of Duphaston tablet orally twice a day from the day of endometrial transformation (Day -5) until ongoing pregnancy was confirmed up to Day 63.

Based on this trial design, predict the completion outcome and termination type (if applicable).